Sagimet reports Q3 2026 results as AURORA Phase 3 acne trial advances
Sagimet dosed its first patient in the pivotal AURORA Phase 3 trial of denifanstat in October 2026 and reported a pro forma cash balance of about $356 million meant to fund operations into mid-2029.
SEC filing